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Immune cells play a key role in host defense against infection and cancer. Upon encountering danger signals,
these cells undergo activation leading to a modulation in their immune functions. However, recent studies
reveal that immune cells upon activation also show distinct metabolic changes that impact their immune
functions. Such metabolic reprogramming and its functional effects are well known for cancer cells. Given
that immune cells have emerged as crucial players in cancer progression, it is important to understand
whether immune cells also undergo metabolic reprogramming in tumors and how this might affect their
contribution in cancer progression. This emerging aspect of tumor-associated immune cells is reviewed
here, discussing metabolic reprogramming of different immune cell types, the key pathways involved, and
its impact on tumor progression.Introduction
The role of immune cells in cancer progression iswell-recognized.
Inflammation and immune evasion are considered as hallmarks of
cancer progression, highlighting the direct involvement of im-
mune cells (Hanahan and Weinberg, 2011). Supporting this fact,
macrophages, which represent one of the major immune infil-
trates in solid tumors, influence various aspect of cancer progres-
sion, e.g., survival and proliferation of cancer cells, angiogenesis,
metastasis, cancer-related inflammation, and immunosuppres-
sion (Biswas and Mantovani, 2010; Qian and Pollard, 2010). Simi-
larly, other studies have indicated the involvement of almost
every immune cell type including T cells, B cells, NK cells, NKT
cells, basophils, neutrophils, dendritic cells (DCs), and myeloid-
derived suppressor cells (MDSCs) in the regulation of cancer
progression (Bindea et al., 2013; Biswas and Mantovani, 2010;
Hanahan and Coussens, 2012). These observations have led to
a major interest in characterizing the immune-microenvironment
in cancer bearers with an aim to design immunotherapies that
target specific immune subsets or their associated molecules in
cancer (Bindea et al., 2013; Quail and Joyce, 2013).
Recent studies have revealed that immune cells possess
distinct metabolic characteristics that influence their immuno-
logical functions. For example, macrophage polarization is
related to distinct metabolic characteristics pertaining to energy
metabolism, iron metabolism, and lipid metabolism (Biswas and
Mantovani, 2010; Jha et al., 2015). Similarly, alterations in
glucose and amino acid metabolism were reported for DCs
and T cells upon activation (Pearce and Pearce, 2013). Taken
together, these studies indicate that metabolic reprogramming
is an important feature of immune cell activation.
Metabolic reprogramming has been suggested as a key hall-
mark of cancer progression (Hanahan and Weinberg, 2011;
Ward and Thompson, 2012). Cancer cells undergo an alteration
in their mode of energy metabolism in order to fulfill the bioener-
getic and biosynthetic needs for rapid cell proliferation, aswell as
to adapt to the tumor microenvironment. While such metabolic
alterations in cancer cells has been long known, a key questionthat has not been investigated to depth is whether tumor-asso-
ciated immune cells also undergo metabolic alterations during
cancer progression. This is a pertinent question given the inte-
gral role of immune cells in cancer and their metabolic character-
istics in other scenarios (e.g., infection, metabolic syndrome).
This issue is reviewed here, highlighting the importance of
metabolic reprogramming in the regulation of tumor-associated
immune cell functions. In addition, some key molecular determi-
nants that mediate the metabolic reprogramming in these cells
and the therapeutic implications that might arise from these find-
ings are also discussed.
Metabolic Reprogramming of Cancer Cells
Cancer cells need to fulfill their bioenergetic and biosynthetic
demands to support rapid proliferation. To do so, they alter their
energy metabolism to a glycolytic mode, even under aerobic
conditions, for rapid energy generation. This aerobic form of
glycolysis is also known as Warburg effect (Ward and Thomp-
son, 2012). Thus, tumor cells get most of their energy through
high consumption of glucose and its conversion into lactic acid
by glycolysis, as opposed to mitochondrial oxidative phosphor-
ylation in normal cells (Figure 1). The glycolytic switch is also a
useful adaptation to survive in the hypoxic tumor microenviron-
ment. The shift to glycolysis is triggered by various mechanisms
reviewed elsewhere (Cairns et al., 2011; Ward and Thompson,
2012). For example, growth-factor signaling activates phosphoi-
nositol 3-kinase (PI3K)-AKT, which induces the expression of
glucose transporters (e.g., GLUT1) and the activation of glyco-
lytic enzymes (e.g., HK2, PFKFB3). Mechanistically, PI3K-AKT
signaling activates mammalian target of rapamycin (mTOR),
which in turn activates the transcription factor, hypoxia-inducible
factor 1 (HIF1). HIF1 cooperates with other transcription factors
or oncogenes such as c-Myc, p53, or Oct1 to induce the expres-
sion of glycolytic genes including GLUT1, HK2, PFKFB3, LDHA,
and suppressors of tricarboxylic acid (TCA) cycle such as PDK
(Cairns et al., 2011; Semenza, 2003; Ward and Thompson,
2012). Moreover, mutations in TCA cycle enzymes such asImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 435
Figure 1. An Overview of Cellular Metabolic Pathways in a Cancer Cell
This diagram depicts some important cellular metabolic pathways and their components. Bold arrows indicate glycolysis and TCA cycle pathway. FA, fatty-acid;
FAS, fatty acid synthase; PDH, pyruvate dehydrogenase. Inset (bottom right panel) shows an overview of keymetabolic pathways and their associatedmolecules
in cancer cells. Blue, black, and grey fonts indicate upregulated, sustained, and inhibited metabolic components, respectively. SDH, FH, and p53 refer to their
mutated versions. Grey lines represent downregulated pathway.
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contribute to the inhibition of this pathway while promoting
glycolysis through HIF1 activation. Collectively, these events
culminate in the metabolic reprogramming of cancer cells to a
predominantly glycolytic mode of energy metabolism (Figure 1).
Cancer cells require high concentrations of glutamine, which is
necessary for supporting robust cell proliferation. Through the
process of glutaminolysis, glutamine is converted to glutamate
by glutaminase (GLS) and then to a-ketoglutarate (a-KG), which
enters the TCA cycle to contribute to amino acid, nucleotide, and
fatty-acid biosynthesis (Figure 1). Mechanistically, c-Myc plays
an important role in promoting glutaminolysis in these cells
(Gao et al., 2009; Wise et al., 2008). In addition, glutamine can
also get converted to glutathione and thus contribute to the
redox state.
Cancer cells undergo changes in their lipid metabolism
acquiring a lipogenic phenotype. The enzyme monoacylglycerol
lipase (MAGL) is highly expressed in cancer cells, where it regu-
lates a pro-tumorigenic lipid network that supports tumor growth
(Nomura et al., 2010). On the basis of the various metabolic
changes discussed above, metabolic reprogramming of cancer436 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.cells is indeed a hallmark of cancer progression (Hanahan and
Weinberg, 2011; Ward and Thompson, 2012).
Metabolic Reprogramming of Immune Cells in Cancer
Recent evidence indicates metabolism as an important regulator
of immune cell phenotype and function (Biswas and Mantovani,
2012; Ghesquiere et al., 2014; Pearce and Pearce, 2013).
Because immune cells are crucial in tumor progression, it is
important to understand howmetabolic alterations in these cells
regulate their pro- or anti-tumor properties.
Macrophages
Macrophages are versatile innate immune cells that contribute to
diverse situations including host defense, homeostasis, and pa-
thology. Although they show phenotypic and functional diversity,
initial studies with defined in vitro stimuli have indicated twomain
macrophage activation or polarization phenotypes. For example,
inflammatory stimuli such as interferon-g (IFN-g)+LPS induce
macrophages to an M1 phenotype characterized by production
of inflammatory cytokines (e.g., interleukin-12 [IL-12], tumor ne-
crosis factor [TNF], IL-6, IL-1), reactive nitrogen and oxygen in-
termediates (RNI, ROI), and microbicidal functions (Biswas and
Immunity
ReviewMantovani, 2010). In contrast, anti-inflammatory stimuli such as
IL-4, IL-13, IL-10, and glucocorticoid or immune complexes
(IC)+LPS induce macrophages to an M2 phenotype character-
ized by decreased production of inflammatory cytokines, in-
creased production of anti-inflammatory cytokines (e.g., IL-10),
and factors that mediate immunosuppression and tissue remod-
eling. However, under in vivo situations such clearcut pheno-
types are often blurred. Therefore, a multi-dimensional rather
than a dichotomous (M1-M2) view of macrophage activation
states was proposed recently wherein these cells integrate envi-
ronmental signals in a stimulus-specific manner to induce spe-
cific functional outcomes (Xue et al., 2014). This necessitates a
common framework to describe macrophage activation states
(Murray et al., 2014).
Macrophages represent a major component of the lympho-
reticular infiltrates in solid tumors and play a crucial role in cancer
progression (Biswas et al., 2013; Murdoch et al., 2008; Qian and
Pollard, 2010). On the one hand, macrophages by producing
RNI, ROI, and inflammatory cytokines (e.g., TNF, IL-1, IL-6)
contribute to genetic alterations and cancer-related inflamma-
tion that leads to tumorigenesis, as noted for many chronic-
inflammation-induced cancers (Biswas et al., 2013; Grivennikov
et al., 2010; Mantovani et al., 2008). On the other hand, these
cells by producing anti-inflammatory cytokines (IL-10, TGF-b),
cathepsins, and metalloproteases (MMPs) promote immuno-
suppression, extracellular matrix remodelling, tumor cell ex-
travasation, and metastasis in established tumors, as well as
regulate response to chemotherapy (Biswas et al., 2013; Griven-
nikov et al., 2010; Mantovani et al., 2008; Quail and Joyce, 2013;
Ruffell et al., 2014). Macrophages by producing various pro-
angiogenic molecules (e.g., EGF, VEGFA) also serve as impor-
tant regulators of tumor angiogenesis (Murdoch et al., 2008).
Although tumor-associated macrophages (TAMs) are generally
described as an M2-like population, evidence suggesting an in-
flammatory (M1-like) phenotype or a phenotypewith overlapping
inflammatory and immunosuppressive features have also been
reported (Franklin et al., 2014; Mantovani et al., 2002; Qian and
Pollard, 2010). In fact, a functional plasticity of TAMs has been
proposed, wherein macrophages show an inflammatory pheno-
type in the early phase of tumor establishment, while displaying
an immunosuppressive phenotype in the later phase of tumor
progression (Biswas et al., 2013) (Figure 2A). This is consistent
with the functional diversity of these cells, the complex and dy-
namic nature of tumor microenvironmental signals in vivo, and
the stage and type of cancer involved.
Polarized macrophages show distinct modes of glucose
metabolism. For example, murine macrophages treated with
the M1 stimuli IFNg+LPS or LPS alone induced increased gly-
colysis, whereas exposure to M2 stimuli IL-4 induced increased
oxidative phosphorylation (Rodriguez-Prados et al., 2010; Tan-
nahill et al., 2013; Vats et al., 2006). Similarly, human monocytes
upon b-glucan stimulation switched to a glycolytic mode, with
concomitant reduction of oxidative phosphorylation (Cheng
et al., 2014). The shift to glycolysis is mediated through the
AKT-mTOR-HIF1a pathway. In murine macrophages, LPS-
induced shift to glycolysis results in the accumulation of the
TCA cycle intermediate, succinate, which via the transcription
factor HIF1a induces the expression of the inflammatory cyto-
kine IL-1b (Tannahill et al., 2013). Glycolysis also induces TNFexpression in macrophages (Dietl et al., 2010). Together, these
observations suggest glycolysis to regulate the inflammatory
phenotype of macrophages.
TAMs show a ‘‘smoldered’’ inflammatory phenotype that pro-
motes cancer-related inflammation (Mantovani et al., 2008).
Importantly, TAMs accumulate in hypoxic areas of tumors where
they express HIF1a (Burke et al., 2003). Because many glycolytic
genes such asGLUT1,HK2, PFKFB3, and PGK1 are regulated by
HIF1a (Semenza et al., 1994), it makes sense that TAMs in such
hypoxic areas of tumors preferentially utilize a glycolytic meta-
bolism tomediate their inflammatory phenotype and support can-
cer-related inflammation. This is consistent with the role of HIF1a
inmyeloid cell-mediated inflammation (Crameret al., 2003).More-
over, HIF1a activation induces RNI production by macrophages,
while the glycolytic shift attenuates TCA cycle activity and mito-
chondrial respiration leading to enhanced ROS production (Peys-
sonnaux et al., 2005; Tannahill et al., 2013). Indeed,macrophages
at the onset of inflammation-induced cancers, through RNI and
ROS production can induce genetic instability and malignant
transformation (Mantovani et al., 2008) (Figure 2A). On the basis
of this, one might speculate that macrophages at the early stages
of tumor onset preferentially utilize a glycolytic mode of energy
metabolism to induce cancer-related inflammation and tumori-
genesis (Figure 2A). A shift to glycolysis also serves as an adapta-
tion for survival in the hypoxic tumor microenvironment.
Lactic acid is an important end-product of glycolysis. Increased
glycolysis in TAMs, tumor cells, and other stromal cells (e.g., can-
cer-associated fibroblast, CAFs) would result in lactic acid accu-
mulation in the tumormicroenvironment (Ghesquiere et al., 2014).
Lactic acid polarizes TAMs to a tumor-promoting phenotype
characterized by the expression of arginase 1 (ARG1), VEGFA,
and several M2 markers via HIF1a activation (Colegio et al.,
2014). Lactic acid can also activate Axl and Tie-2 receptors that
drive an immunosuppressive and pro-angiogenic macrophage
phenotype, supporting tumor promotion (Lemke and Lu, 2003;
Lewis et al., 2007; Ruan and Kazlauskas, 2013). In contrast, tu-
mor-derived lactic acid was reported to upregulate the pro-in-
flammatory cytokine IL-23 in human macrophages and murine
TAMs from B16 melanoma, upon BCG treatment (Shime et al.,
2008). Such opposite effects might be explained by the dynamic
changes in lactic acid levels in growing tumors, which could
induce differential macrophage responses in line with their func-
tional plasticity in tumors (Biswas and Mantovani, 2010).
IL-4 is a well-known M2-polarizing macrophage stimulus.
In PyMT-MMTV-driven spontaneous mammary carcinoma,
Th2 cell-derived IL-4 polarized TAMs to an immunosuppressive
(M2) phenotype (DeNardo et al., 2009). Because IL-4 promotes
oxidative phosphorylation in macrophages (Vats et al., 2006), it
might be speculated that TAMs in such tumors preferentially uti-
lize oxidative phosphorylation instead of glycolysis.
Given the heterogeneity and dynamic nature of tumormicroen-
vironment across different cancers, as well as different stages of
the same cancer, it is quite likely that the mode of glucose meta-
bolism in TAMs might also vary across these conditions. For
example, TAMs from the early inflammatory phase of cancer
onsetmight showglycolysis,while those in the later stagesof can-
cermight showoxidative phosphorylation (Figure 2A). The shift to
oxidative phosphorylation could be mediated by IL-4 from Th2
cells that infiltrate established tumors, as well as by other factorsImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 437
Figure 2. Metabolic Reprogramming of TAMs, TADCs, and T Cells and Their Altered Functions during Tumor Progression
An overview of the possible alterations in key metabolic processes, their component molecules, and its effect on pro-tumor functions for the indicated immune
cell type is presented.
(A) Proposed metabolic shift in TAMs during tumor progression. During tumor onset, inflammatory macrophages through a glycolytic shift, HIF1a activation, and
an inhibited OXPHOSP mediate the expression of NO, ROI, IL-1b, and TNF, to support genetic instability and cancer-related inflammation that leads to
tumorigenesis. HIF1a-induced expression of the angiogenic molecule VEGFA is also shown. In TAMs from established tumors, AMPK activation via nutrient
deprivation, lactate accumulation, Th2-derived IL-4 (which activates c-Myc, p53, STAT6, PGC1b), and activated PKM2 suppresses glycolysis, while upregulating
OXPHOSP. This induces immunosuppressive macrophages that promote tumor growth. Changes in amino acid, iron, and fat metabolism that contribute to this
process are also indicated.
(B) TADCs also show metabolic alterations during tumor progression. TADCs encounter tumor-derived DAMPs and hypoxia to upregulate glycolysis via an early
TBK1-IKKε and/or later PI3K-AKT-HIF1a pathway. HIF1a impairs DCmaturation and upregulates A2b andNO expression (which inhibits OXPHOSP). Adenosine-
A2b interaction induces an immunosuppressive and pro-tumor cytokines. The growing tumor progressively imposes nutrient deprivation, which activates AMPK
in TADCs. This together with lactate accumulation leads to possible inhibition of glycolysis and upregulation of OXPHOSP in the TADCs. Amino acid uptake from
the tumor microenvironment, its metabolism, and MSR1-mediated lipid accumulation further promotes immunosuppressive events to support tumor growth.
(C) Tumor microenvironment inhibits T effector cells and promotes Treg development. Depletion of extracellular amino acids (via uptake by tumor and other
stromal cells), lactate accumulation, and nutrient deprivation-induced AMPK activation inhibits TCR signaling and its downstream glycolysis (indicated by red T
symbol) in T effector cells (e.g., CD8+ cytotoxic T cells). This results in inhibition of proliferation and effector functions. Inhibition of glycolysis by AMPK, activation
of OXPHOS and FAO, and tumor microenvironment-derived factors (e.g., TGF-b, IL-10, Kyn, and hypoxia) instead promotes Treg development. This supports
immune evasion and tumor growth. Black arrows and blue font in T-effector cell represent their metabolic state following activation through TCR-CD3 and CD28.
However, these (except AMPK) are inhibited in tumor settings as mentioned above. In (A) and (B), although two different phenotypes of TAMs and TADCs are
indicates for easy depiction, some of these characteristics may overlap in vivo due to the plasticity of these cells and multiplicity of tumor microenvironmental
stimuli. Blue, black, and grey fonts indicate upregulated, sustained, and inhibited metabolic components, respectively. Dashed lines indicate likely (unproven)
interactions. OXSPHOS: Oxidative phosphorylation; Arg, Arginine; Orn, Ornithine; Gln, glutamine; Trp, tryptophan; Kyn, Kynurenine; FAS, Fatty acid synthesis;
FAS*, Fatty acid synthase.
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as well as induces an immunosuppressive and tissue remodeling
macrophage phenotype, as discussed above (Colegio et al.,
2014; Dietl et al., 2010). Another example is the glycolytic enzyme438 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.pyruvate kinase, PKM2, which in its inactive dimeric formbinds to
HIF1a and helps in IL-1b expression in inflammatory macro-
phages, whereas in its active tetrameric form inhibits glycolysis,
driving macrophages to an immunosuppressive, M2 phenotype
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onset, inflammatory TAMs induce PKM2 expression, which upon
subsequent activation (in its tetrameric form) switches these cells
to an immunosuppressive (M2) phenotype in the established tu-
mors (Figure 2A). It would be interesting to investigate whether
TAMs actually display such metabolic plasticity and whether
this is a cause or an effect of their functional plasticity in course
of tumor progression.
Polarized macrophages display distinct modes of L-arginine
metabolism (Rath et al., 2014). IFNg+LPS-stimulated macro-
phages upregulate inducible nitric oxide synthase (iNOS or
NOS2), which catalyzes the conversion of L-arginine into nitric
oxide (NO) and L-citrulline (Figure 2A). In contrast, lL-4-treated
macrophages upregulate ARG1 (Liver type) which catalyzes
the conversion of L-arginine to L-ornithine and synthesis of poly-
amines (Modolell et al., 1995). These distinct modes of arginine
metabolism have distinct functional consequences with macro-
phage NO production showing microbicidal and tumoricidal
effects (Stuehr and Nathan, 1989), whereas ARG1-mediated
polyamine production support cell proliferation, collagen synthe-
sis, and tissue remodeling, relevant to tumor growth (Chang
et al., 2001). Indeed, tumor-promoting TAMs from murine fibro-
sarcoma, Lewis lung carcinoma, B16 melanoma, and BW-Sp3
model show elevated ARG1 expression (Biswas et al., 2008;
Sharda et al., 2011). In addition, Arg1 expression by TAMs can
also mediate T cell immunosuppression (Kusmartsev and Gabri-
lovich, 2005), as discussed in the myeloid-derived suppressor
cells (MDSCs) section. In a different setting, interaction with
tumor cells induced Toll-like receptor (TLR)1-mediated NO ex-
pression bymacrophages, which was instrumental in supporting
post-radiotherapeutic tumor re-growth (Ryu et al., 2015)
Another important metabolic pathway in macrophages is the
glutamine-glutamate pathway. Macrophages have high rates
of glutamine utilization and express high levels of glutaminase,
a key enzyme in glutamine metabolism. Early in vitro experi-
ments indicated glutamine to be essential for cytokine produc-
tion (e.g., TNF, IL-1, IL-6), antigen presentation, and phagocy-
tosis in murine macrophages (Newsholme, 2001). Recent
metabolic profiling demonstrated a preferential enrichment of
several metabolites and genes of the glutamine metabolism (glu-
taminolysis) pathway (e.g., glutamate, AKG,GPT2, andGATM) in
IL-4-induced M2 macrophages (Jha et al., 2015). In these cells,
glutamine was essential for supporting an active TCA cycle
and the UDPGlcNAc synthesis pathway, which is required for
N-glycosylation. Accordingly, glutamine regulated the expres-
sion of M2 markers like the N-glycosylated receptor CD206, as
well as IRF4, KLF4, and CCL22. Supporting these observations,
TAMs from Lewis lung carcinoma, which show an M2 pheno-
type, also displayed higher gene expression of glutamine meta-
bolism enzymes, transaminase (GPT), and glutamine synthetase
(GLUL) (Colegio et al., 2014). However, whether and how gluta-
mine metabolism regulates the tumor-promoting functions of
TAMs needs to be clarified in future studies. The metabolism
of other amino acids such as tryptophan in tumor associated
myelomonocytic cells is discussed under MDSCs section (see
below).
Macrophages can alter their lipid metabolism in response to
distinct microenvironmental stimuli (Dennis et al., 2010; Martinez
et al., 2006). For example, IL-4-activated mouse macrophagesupregulate fatty-acid uptake and fatty-acid oxidation (FAO),
whereas this is suppressed in IFNg+LPS-activated macro-
phages (Odegaard and Chawla, 2011). Uptake of triacylglycerol
(TAG) and their subsequent lysosomal lipolysis were found to be
essential for FAO andM2 activation in these IL-4-treated macro-
phages (Huang et al., 2014). Mechanistically, IL-4 via STAT6
triggered the expression of coactivator peroxisome prolifera-
tor-activated receptor (PPAR)g-coactivator-1b (PGC-1b), which
orchestrated the switch to mitochondrial respiration and
FAO (Odegaard and Chawla, 2011). The nuclear receptors per-
oxisome proliferator activated receptor (PPAR) and liver X
receptor (LXR) mediate macrophage response to lipids, dis-
cussed further in the next section. Polarized macrophages also
show distinct changes in arachidonic acid metabolism with
IFNg+LPS-treated macrophages upregulating cyclooxygenase
2 (COX2) and microsomal isoform of PGE synthase (mPGES),
but downregulating COX1, whereas IL-4-treated macrophages
displaying the reverse trend, as detailed elsewhere (Biswas
and Mantovani, 2012; Martinez et al., 2006; Mosca et al., 2007).
In a tumor setting, macrophages undergo changes in their lipid
profile. A study in Lewis lung carcinoma showed differential lipid
profiles in macrophages and cancer cells (Poczobutt et al.,
2013). Leukotriene (LTB4, LTC4, LTD4) production was mainly
from myelomonocytic cells, whereas prostaglandin (PGE2,
PGD2, PGF2) production was from both myelomonocytic and
cancer cells. Moreover, alveolar macrophages and infiltrating
TAMs differed in eicosanoid profiles, with the former expressing
COX1 (not COX2), 5-lipoxygenase and leukotreines, while the
latter expressing COX2 and prostaglandins. In the same tumor
model, expression of fatty-acid synthase in TAMs polarized
these cells to an IL-10-expressing, pro-tumor phenotype (Park
et al., 2015). In another study, E-FABP-expressing TAMs were
shown to produce high levels of IFN-b through upregulation of
lipid droplet formation (Zhang et al., 2014). This IFN-bwas instru-
mental for recruitment of NK cells and anti-tumor activity. These
evidences suggest differential lipid metabolism in TAMs leading
to pro- or anti-tumor functions, although the mechanism linking
lipid metabolism to the functional outcome remains unclear.
Iron homeostasis is an important metabolic aspect of macro-
phages. Polarized macrophages show differential modes of iron
metabolism. IFNg+LPS-treated M1 macrophages express low
levels of the iron exporter, ferroportin, but high levels of H-ferritin,
which involved in iron storage (Cairo et al., 2011). Conversely, IL-
4-treated M2 macrophages express low levels of H-ferritin, but
high levels of ferroportin. In line with this profile, M1 macro-
phages are believed to favor iron sequestration and hence
restrict bacterial and cancer growth, whereas M2 macrophages
favor iron release which promotes tissue repair and tumor cell
proliferation (Cairo et al., 2011; Recalcati et al., 2010). Support-
ing this concept, upregulation of another iron releasing protein,
lipocalin (LCN) in TAMs supported the proliferation of human
breast cancer cells (Jung et al., 2015). The iron-releasing
enzyme, hemeoxygenase-1 (HO-1) metabolizes heme to carbon
monoxide, biliverdin, and ferrous iron. In a 4T1 mammary carci-
noma model, suppression of HO-1 in TAMs was shown to skew
their polarization from anM2 to anM1 phenotype that correlated
with reduced tumor growth (Deng et al., 2013). Furthermore,
intracellular iron level by regulating prolyl hydroxylases controls
the stability of HIF1a that is crucial for the survival and pro-tumorImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 439
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above findings provide ample evidences for the regulation of
macrophage pro-tumor function by iron metabolism (Figure 2A).
Dendritic Cells
DCs are professional antigen-presenting cells that bridge innate
and adaptive immunity. Upon sensing danger signals such as
pathogen-associated or tissue-damage-related stimuli, imma-
ture DCs get activated and undergo maturation, which involves
an upregulation of antigen-presenting molecules (e.g., major his-
tocompatibility complex, MHCII, CD80, CD86, CD40), cytokines
(e.g., IL-12), and chemokine receptors (e.g., CCR7). Matured
DCs migrate to the lymphoid organs where they present antigen
and activate a T cell response. In contrast to this scenario, DCs
can also promote immune tolerance and immune evasion under
certain circumstances. For example, DCs from tumor bearers
(i.e., tumor associated DCs, TADCs) show an impaired ability
to trigger immune response, while promoting immunosuppres-
sion (Apetoh et al., 2011; Dong and Bullock, 2014; Tran Janco
et al., 2015). Accumulation of immature DCs, decreased number
of functionally competent DCs, and matured DCs with impaired
functions have been reported for several murine and human can-
cers (Gabrilovich et al., 2012). Although themechanism(s) behind
the impaired functionality of TADCs is still not well understood, a
new perspective to the problem emerges with recent data on
metabolic regulation of DC functions (Malinarich et al., 2015;
Pearce and Everts, 2015; Ravindran et al., 2014).
DCs utilize oxidative phosphorylation under resting state,
but shift to a glycolytic metabolism upon activation (Figure 2B,
left panel). During the early phase of activation by TLR ligands,
glycolysis is necessary for inducing an activation pheno-
type characterized by the upregulation of CD40, CD86, and
IL-12p40, whereas during the later phase, glycolysis is dispens-
able for activation but necessary for DC survival (Krawczyk et al.,
2010). Concomitant with the increased glycolysis activated DCs
show a decrease in oxidative phosphorylation. The decreased
oxidative phosphorylation is suggested to be mediated by
NOS2-induced NO production (which inhibits the electron trans-
port chain enzyme, cytochrome c oxidase) and activation of
PI3K-AKT pathway (which inhibits AMP-activated protein ki-
nase, a key regulator of oxidative phosphorylation) in the TLR-
stimulated DCs. Collectively, these findings indicate glycolysis
as key metabolic regulator of DC activation.
In the tumor microenvironment, various factors might impair
the activation, maturation, and function of TADC. For example,
the effect of hypoxia on DCs is not fully understood. In mice
studies, hypoxia enhanced DC maturation (Jantsch et al.,
2008). This involved the accumulation of HIF1a, induction of
glycolysis-related HIF target genes and increased glycolysis. In
contrast, hypoxia impaired the maturation and migration of
human monocyte-derived DCs (Mancino et al., 2008). This
apparent contradiction might be explained by the fact that
hypoxia induces progressive accumulation of metabolites like
adenosine and lactic acid in the tumor microenvironment, which
might negatively impact DC activation. Indeed, hypoxia upre-
gulated adenosine receptor (A2b) on human DCs and switched
them to a Th2 promoting phenotype (Yang et al., 2010). The
interaction of adenosine-adenosine receptor impairs DC differ-
entiation and function. Such DCs show impaired allostimulatory
activity, enhanced expression of IL-6, COX2, TGF-b, IL-10, IL-8,440 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.and VEGFA, and promoted tumor growth (Novitskiy et al., 2008).
IL-10 and TGF-b would support T regulatory (Treg) cells, as
reported for tumor-conditioned DCs (Dumitriu et al., 2009)
(Figure 2B, left panel).
TADCs upregulate the immune checkpoint receptor PD-1 and
its ligand PD-L1 (Tran Janco et al., 2015). Because PD-L1 is a
HIF1a target gene (Noman et al., 2014), it not difficult to specu-
late that tumor hypoxia would induce PD-L1 on DCs and propa-
gate immune evasion (Figure 2B, left panel). Lactic acid also
induces an impaired phenotype in DCs, similar to the TADCs
(Gottfried et al., 2006). Moreover, in the tumor microenviron-
ment, rapidly growing cancer cells impose nutrient competition
and accumulation of metabolites like adenosine, which might
trigger the metabolic sensor AMP-activated protein kinase
(AMPK) in TADCs. AMPK is known to promote oxidative phos-
phorylation and inhibit glycolysis (Figure 2B right panel). This
might provide a possible metabolic explanation for the impaired
activation of TADCs. In support, tolerogenic DCs display a meta-
bolic signature of increased oxidative phosphorylation that reg-
ulates their tolerogenic function (Malinarich et al., 2015). Future
metabolic studies in TADCs should clarify whether they actually
switch from glycolysis to oxidative phosphorylation in course of
tumor progression.
TADCs through the expression of amino acid metabolism en-
zymes such as ARG1, NOS2, and Indoleamine 2,3-dioxygenase
(IDO) mediate immunosuppression (Figure 2B). Like macro-
phages andMDSCs, ARG1 and IDO expression in TADCs exerts
depletion of arginine and tryptophan in the tumor microenviron-
ment, which has inhibitory effects on CD8+ T cell response and
survival (Tran Janco et al., 2015), see MDSC section for further
details. In addition, vitamin A metabolism to retinoic acid in
TADCs was recently shown to drive Treg cell and tolerogenic
response in melanoma (Hong et al., 2015).
Modulation of lipid metabolism such as de novo fatty-acid
synthesis during DC activation affects ER and golgi expansion
that impacts their antigen-presenting ability (Everts et al.,
2014). TADCs express scavenging receptors like MSR1, which
facilitate lipid uptake and accumulation (Herber et al., 2010).
Lipid accumulation in these cells in turn impairs DC functions
like tumor antigen presentation and allogeneic T cell response.
It is tempting to speculate whether switching of TADCs from
glycolysis to oxidative phosphorylation in the nutrient-deficient
microenvironment of established tumors might favor fatty-acid
synthesis and lipid accumulation, thereby contributing to their
tolerogenic state. Nutrient starvation in tumor microenvironment
also induces ER stress. Interestingly, the ER stress response fac-
tor XBP1 was shown to induce abnormal lipid accumulation via
triglyceride biosynthetic program in TADCs, impairing its ability
to support anti-tumor T cell response, thereby promoting ovarian
cancer progression (Cubillos-Ruiz et al., 2015).
Despite their role in tumor promotion, DCs—due to their
inherent capacity to present antigen and trigger an immune
response—have been studied extensively in the context of tumor
vaccines to boost an anti-tumor response (Apetoh et al., 2011).
More recently, vaccines were shown to upregulate the nutrient
sensor GCN2 in DCs to induce a CD8+ T cell response (Ravin-
dran et al., 2014). How vaccine-mediated modulation of DC
metabolism might contribute to their anti-tumor response would
be interesting to study.
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T cells are key players in the host immune response to cancer.
On the one hand, activated CD8+ T cells exert a direct and potent
cytotoxic effect on tumor cells. On the other hand, activated
CD4+ T cells differentiate into effector subtypes that either sup-
port or repress cancer growth. For example, CD4+ Th1 cells
through IFN-g secretion can activate macrophages and NK cells
to induce an anti-tumor response, whereas CD4+ Th2 cells and
Treg cells can promote tumor-induced immunosuppression. De-
pending on the context, Th17 cells can either support or inhibit
tumor progression (Bailey et al., 2014).
T cells show distinct changes in metabolism depending on
their activation and differentiation, reviewed extensively else-
where (Pearce and Pearce, 2013; Siska and Rathmell, 2015).
Naive T cells generate most of their energy through FAO,
oxidative phosphorylation, and low levels of glutamine meta-
bolism during the quiescence state. However, upon activation,
these cells (differentiating into T-effector cells) have increased
bioenergetic and biosynthetic needs to support rapid prolifer-
ation. To meet this, they increase nutrient uptake (e.g.,
glucose, amino acids) and upregulate glycolysis and glutami-
nolysis, while suppressing FAO (Figure 2C, right panel).
However, oxidative phosphorylation is still maintained. Gluta-
minolysis and increased Pentose Phosphate Pathway (PPP)
contribute to biosynthetic purposes, while glycolysis is re-
quired for T cell effector functions (Chang et al., 2013). Mech-
anistically, downstream of T cell receptor (TCR) and CD28, a
PI3K-AKT-mTOR pathway activates transcription factors like
HIF1a and c-Myc (Siska and Rathmell, 2015). This in turn upre-
gulates glucose transporters (GLUT1), metabolic enzymes
(e.g., HK2), and amino-acid transporters (e.g., solute carrier
proteins SLC7A5), which facilitate glycolysis and glutamine
metabolism (glutaminolysis). Recently, TCR-dependent uptake
of glutamine and leucine was reported to be mediated by
the amino acid transporter ASCT2, which in turn led to
mTOR activation and the development of Th1, Th17, and in-
flammatory T cell response (Nakaya et al., 2014). Interestingly,
Treg cells and memory CD8+ T cells depend largely on oxida-
tive phosphorylation for their energy metabolism (see below)
(Figure 2C, left panel). The importance of amino-acid meta-
bolism pertaining to arginine, tryptophan, glutamine, and cy-
steine on T cell effector function is discussed in the MDSC
section. Fatty-acid metabolism is also an important regulator
of T cell differentiation with de novo fatty-acid synthesis and
FAO promoting T effector and Treg cell development, respec-
tively (Lochner et al., 2015). De novo fatty-acid synthesis
through acetyl-CoA carboxylase (ACC) was shown to be crit-
ical for Th17 cell differentiation, while preventing a Treg cell
phenotype (Berod et al., 2014). Generation and survival of
CD8+ memory T cells requires oxidative metabolism and FAO
(van der Windt et al., 2012). These cells concurrently use
fatty acid synthesis and FAO to meet their metabolic demands
(O’Sullivan et al., 2014). In agreement, TAG synthesis was
implicated in CD8+ memory T cell survival (Cui et al., 2015).
Mechanistically, an orphan protein, lymphocyte expansion
molecule (LEM) has recently been reported to control oxidative
phosphorylation and mitochondrial ROS production in CD8+
T cells, thereby boosting memory T cell numbers and protec-
tive response against virus and cancer (Okoye et al., 2015).High glycolytic activity of proliferating tumor cells coupled with
the poor vasculature within tumors can induce amino acid and
nutrient depletion. Such a situation would impair TCR signaling,
glycolytic metabolism and the anti-tumor effector functions of
T cells (Figure 2C, right panel). However, Treg cells, whichmainly
rely on FAO rather than glycolysis, can survive under these con-
ditions and exert their immunosuppressive effect (Macintyre
et al., 2014; Michalek et al., 2011) (Figure 2C, left panel). In
fact, expansion of Treg cells has been linked to the activation
of AMPK, a sensor of nutrient stress. In addition, accumulation
of metabolic wastes such as lactate and amino acid metabolic
products like kynurenine can also suppress T cell activation
and cytotoxic activity, while promoting Treg cells (Siska and
Rathmell, 2015). Furthermore, tumor hypoxia via HIF1a can pro-
mote the expansion of Treg cells and induction of PD-L1 (Ben-
Shoshan et al., 2008; Noman et al., 2014). Taken together, these
observations indicate how the tumor microenvironment might
shape the metabolic reprogramming of T cells, thereby modu-
lating their effector functions to support immunosuppression
(Figure 2C).
MDSCs
MDSCs are a heterogeneous group of immature myelomono-
cytic cells that are functionally defined by their potent immuno-
suppressive activity on T cells (Gabrilovich et al., 2012). These
cells expand greatly in tumor bearers and were originally charac-
terized by a CD11b+Gr1+ phenotype in tumor-bearing mice.
MDSCs are classified into monocytic MDSCs and granulocytic
MDSCs, both of which can induce suppression of antigen-acti-
vated CD8+ T cells.
Amino acid metabolism and oxidative stress play a pivotal role
in mediating the suppressive activity of MDSCs on T cells. This is
mediated by mainly two mechanisms: (1) depletion of amino
acids essential to T cells and (2) generation of oxidative stress
via reactive species (Gabrilovich et al., 2012) (Figure 3).
MDSCs can deplete L-arginine through its metabolism via
ARG1 expression. Similarly, MDSCs can cause L-cysteine depri-
vation through its sequestering (Srivastava et al., 2010). Deple-
tion of these amino acids leads to the downregulation of z-chain
of the T cell receptor and inhibition of T cell proliferation.MDSCs,
like macrophages and DCs, express the inducible enzyme IDO,
which catalyzes tryptophan metabolism along the kynurenine
pathway (Martinez et al., 2006; Munn et al., 1999). Thus, IDO ex-
erts its inhibitory effect on T cells via tryptophan deprivation (by
metabolizing it), as well as by inducing the expansion of Treg
cells (Grohmann and Bronte, 2010; Saxena et al., 2007). Corrob-
orating with this, MDSCs were found to promote expansion of
Treg cells in B cell lymphoma (Serafini et al., 2008).
MDSCs subsets by expressing NOS2, ARG1, and NADPH ox-
idase induce the production of RNI (e.g., NO, peroxynitrite) and
ROI (e.g., H2O2) (Gabrilovich et al., 2012). These reactive species
downregulate the z-chain of TCR and IL-2 receptor signaling, in-
hibiting T cell activation and proliferation. Monocytic MDSCs
mainly induce their inhibitory effect via NO while granulocytic
MDSCs do so via ROI.
While the crucial role of nitrogen metabolism in regulating the
immunosuppressive functions ofMDSCs in tumor settings is well
established, relatively little is known about the other metabolic
pathways in these cells. Enhanced carbon metabolism (glycol-
ysis, glutaminolysis, and TCA activity) and its crosstalk withImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 441
Figure 3. Metabolic Crosstalk between Cancer Cells and Indicated Stromal Cells Showing Their Metabolic Reprogramming and Altered
Functions in Tumors
Metabolic alterations in the indicated non-immune (e.g., CAFs, endothelial cells) and immune stromal cells (MDSCs, B cells, NK cells, neutrophils) are presented.
Blue, black, and grey fonts indicate upregulated, sustained, and inhibited metabolic components, respectively. Dashed lines indicate likely (unproven) in-
teractions. Arg, Arginine, Orn, Ornithine; Gln, glutamine; Trp: tryptophan; Kyn, Kynurenine; FAS, Fatty acid synthesis.
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relationship with the increased expression of AMPK and SIRT,
which are known to interfere with glycolysis, needs to be clarified
(Hammami et al., 2012; Liu et al., 2014) (Figure 3). Recently,
increased fatty-acid uptake and FAO was also demonstrated
to regulate the immunosuppressive function of tumor infiltrating
MDSCs (Hossain et al., 2015).
Neutrophils
Tumors are known to release chemokines that recruit neutro-
phils. Tumor-associated neutrophils (TANs) can have both pro-
and anti-tumor effects (Mantovani et al., 2011). In the absence
of tumor-derived TGF-b, TANs encouraged CD8+ T cells
response and anti-tumor activity, whereas in the presence of
TGF-b, exhibited tumor promoting activity. TANs produce
several factors like arginase 1, ROI, cathepsins, MMPs, and
pro-angiogenic cytokines, which promote tumor growth, angio-
genesis, and metastasis.
Metabolically, neutrophils are strongly committed to aerobic
glycolysis and PPP as the dominant mode of energy metabolism442 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.(Figure 3). This is in line with the fact that these cells possess few
mitochondria,which are however are not used inATPproduction,
but for maintaining redox balance, essential for cell survival.
Glycolysis and PPP contribute to neutrophil functionality. For
example, PPP pathway produces NADPH, which is a cofactor
for NADPH oxidase, a key enzyme mediating neutrophil micro-
bicidal functions. Studies on glucose-6-phosphate transporter
deficiency in human neutrophils also implicated glycolysis in
the regulation of important neutrophil functions like oxidative
burst and chemotaxis (Jun et al., 2014). Another important func-
tionof neutrophils is the formationof neutrophil extracellular traps
(NETs), a mixture of DNA, histones and anti-microbial peptides
that traps and kills bacteria. Glucose uptake, glycolysis, and a
metabolic shift toward PPP are essential for NETs formation
(Azevedo et al., 2015; Rodriguez-Espinosa et al., 2015). NETs
can sequester circulating tumor cells and promote metastasis
(Cools-Lartigue et al., 2013). Moreover, NETs were observed to
accumulate in the vasculature of tumor-bearing mice, which
was associated with proinflammatory adhesion molecules and
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vall et al., 2015). Collectively, these data provide some sugges-
tions as to how metabolic change in neutrophils by regulating
functions like NETs might contribute to tumor progression.
Further characterization of neutrophil function relating to cancer
and their regulation by cell-intrinsic metabolism is now needed.
Natural Killer Cells
Natural killer (NK) cells by producing IFN-g and cytotoxic mole-
cules like granzyme play an integral role in activating an anti-tu-
mor T cell response and tumor cell killing. A recent study in pri-
mary murine NK cells showed them to mainly utilize oxidative
phosphorylation under resting conditions and upon short-term
activation (Keppel et al., 2015). However, upon prolonged culture
with high-dose of IL-15, NK cells showed increased glycolytic
metabolism. This is consistent with another recent study, which
confirmed NK cells to show heightened glycolysis upon activa-
tion (Donnelly et al., 2014). Glycolysis was shown to regulate
granzyme B and IFN-g expression by activated NK cells. In the
tumor microenvironment, hypoxia and IL-15 would promote
glycolysis in NK cells, supporting their anti-tumor activity
(Figure 3). It would be interesting to investigate how different tu-
mor-associated stimuli impact NK activation and metabolism,
thereby modulating their anti-tumor response.
B Cells
B cells via antibody production and immune complexes can
modulate myeloid cells function to support tumor progression
(Andreu et al., 2010; de Visser et al., 2005). Recently, LPS or an-
tigen-stimulated activation of B cells was shown to trigger a
balanced increase in both glycolysis and mitochondrial meta-
bolic activity (Caro-Maldonado et al., 2014). However, BAFF-
mediated chronic stimulation poised them for rapid induction
of aerobic glycolysis and a Glut1-dependent metabolic reprog-
ramming that was necessary for antibody production (Figure 3).
Mechanistically, c-Myc but not HIF1a was implicated in medi-
ating the metabolic changes in B cells. Given that many tumors
express BAFF, it remains to be seen how B cell metabolic re-
programming might affect their contribution to tumor progres-
sion.
Other Stromal Cells
In addition to the immune cells discussed above, NKT cells,
innate lymphoid cells, basophils, and mast cells have been
shown to contribute to tumor progression (Biswas and Manto-
vani, 2012). However, the metabolic control of these cell types
in the tumor microenvironment remains unknown. Endothelial
cells and cancer associated fibroblasts (CAFs) are two important
stromal cell types that have a strong influence on tumor associ-
ated immune cells, tumor cells, and tumor progression (Ghes-
quiere et al., 2014) Endothelial cells are highly glycolytic cells
that depend on this pathway for almost 85% of their energy
(Figure 3). Glycolysis, PPP, and glutamine metabolism regulate
vascular sprouting, proliferation, and survival of these cells.
PFKFB3 is a key regulator of glycolysis in these cells. Similarly,
proliferating CAFs display increased glycolytic flux and gluta-
mine metabolism, but possess a truncated TCA cycle at citrate.
In fact, CAFs are ‘‘hijacked’’ by the cancer cells for the produc-
tion of lactic acid, amino acids, and ketone bodies, which supply
nutrients for the cancer cells. Cancer cells in turn produce ROS
that activates HIF1a in CAFs to maintain their glycolytic meta-
bolism (Figure 3). Recently, reprogramming of glucose andamino acid metabolism in CAFs via a p62-mTorc1-c-Myc
pathway was linked to tumor promotion through increased
ROS and IL-6 production (Valencia et al., 2014). A detailed ac-
count of the metabolic reprogramming of endothelial cells and
CAFs is presented by Ghesquiere et al. (2014).
Molecular Determinants of Metabolic Reprogramming
of Immune Cells in Cancer
Accumulating evidence suggests the metabolic reprogramming
of immune cells in tumor settings. But the molecular mecha-
nism(s) that drives this process is far from clear. We discuss
below a few important molecules that regulate metabolism in im-
mune cells and how they might mediate the metabolic reprog-
ramming of these cells in the tumor microenvironment.
PI3K-AKT Pathway
Stimulation of immune cells like macrophages, DCs by TLR li-
gands (e.g., LPS, CpG), or T cells via TCR-CD3 and CD28
signaling triggers activation of the PI3K-AKT pathway. Depend-
ing on the cell type, PI3K induces the expression of glucose
transporter GLUT1 (in DCs, macrophages) and key glycolysis
enzymes like HK2 and phosphofructokinase 2 (PFK2). Accord-
ingly, the role of PI3K-AKT in glycolysis is reported for all the
three cell types mention above (Chang et al., 2009; Cheng
et al., 2014; Krawczyk et al., 2010; Siska and Rathmell, 2015)
(Figures 2 and 3). Because tumor microenvironmental factors
like versican, HMGB1, and DAMPs can stimulate the TLR
pathway, it is reasonable to speculate that signaling through
TLR and other receptors (G protein coupled receptors, receptor
tyrosine kinases) would activate PI3K-AKT in infiltrating myeloid
cells like TAMs leading to glycolysis and the promotion of can-
cer-related inflammation (Schmid et al., 2011). PI3K-AKT activa-
tion in TAMs and mast cells was shown to promote colitis-
induced cancer (Khan et al., 2013). In a pancreatic andmammary
cancer model, PI3K activation in tumor infiltrating CD11b+
myeloid cells was implicated in resistance to anti-angiogenic
therapy (Rivera et al., 2015). PI3K-AKT activation in GM-CSF-
derived DCs induced the negative regulator disabled-2 adaptor
protein (DAB2), which inhibited CTL response against tumors
and promotes immunosuppressive phenotypes (Ahmed et al.,
2015). Such a phenotype is reminiscent of TADCs. PI3K-AKT is
also a survival signal that would promote the survival of immune
cells in the hostile tumor microenvironment. Collectively, these
evidences suggest PI3K-AKT pathway to be an important regu-
lator of glycolysis in immune cells, as well as to drive these cells
to a tumor promoting phenotype.
mTOR
mTOR is an important regulator of metabolism in immune cells
that couples nutrient sensing to metabolic outcomes like glycol-
ysis, fatty-acid synthesis, and protein synthesis. mTORmediates
metabolic processes like glycolysis by enhancing the expression
of HIF1a (Cheng et al., 2014; Howell andManning, 2011) (Figures
1 and 2). mTOR is a downstream target of AKT signaling not only
in DCs and T cells (Krawczyk et al., 2010), but in all mammalian
cells. However, its role in DCs is still not clear. mTOR inhibition by
rapamycin in murine GM-CSF-derived BMDCs enhanced immu-
nostimulatory and anti-tumor activity, whereas its inhibition in
human monocyte-derived and plasmacytoid DCs downregu-
lated pro-inflammatory cytokines and CD8+ T cell response
(Dong and Bullock, 2014). In macrophages, constitutiveImmunity 43, September 15, 2015 ª2015 Elsevier Inc. 443
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remodeling M2 phenotype that was in line with the phenotype
of TAMs in established tumors (Byles et al., 2013). However,
promotion of this phenotype was linked to PI3K inhibition by
mTOR through a negative feedback loop. In T cells, TCR sig-
naling can activate mTOR. mTOR activation sustained glycolysis
and effector functions in CD8+ T cells, as well as differentiation of
T cells into distinct subsets like Th1, Th2, or Th17 (Siska and
Rathmell, 2015). In contrast, mTOR inhibited the development
of Treg cells, which rely mainly on FAO (Michalek et al., 2011).
mTOR also contributes to the survival of immune types. Although
the tumor microenvironmental stimuli, which induce mTOR acti-
vation in immune subsets, is not yet well understood, it is
conceivable that mTOR activation in these tumor-associated im-
mune cells would modulate their metabolism to support survival,
differentiation, and tumor-promoting functions.
AMPK
AMPK is a well-known molecule of metabolic interest and a key
regulator of oxidative phosphorylation. Because IL-4-activated
macrophages preferentially induce oxidative phosphorylation,
this and other anti-inflammatory factors like IL-10, TGF-b,
and STAT3 were shown to induce rapid AMPK activation in
macrophages, driving them to an immunosuppressive pheno-
type (Sag et al., 2008; Zhu et al., 2015). Conversely, inflammatory
stimuli like LPS that preferentially induce glycolysis, suppressed
AMPK activation in macrophages (Sag et al., 2008). In DCs,
AMPK activation was shown to suppress glucose consumption
and LPS-induced IL-12p40 expression, indicating impaired
maturation (Krawczyk et al., 2010). In T cells, AMPK activation
has been implicated in diverse functions like suppression of T
effector function, promotion of T regulatory function, and the
generation of CD8+memory T cells (Michalek et al., 2011; Pearce
and Pearce, 2013; Siska and Rathmell, 2015) (Figure 2C). Impor-
tantly, a key role of AMPK is nutrient sensing via its activation by
LKB1.
Based on the above facts, it is conceivable that various factors
in the tumor microenvironment such as nutrient deprivation,
adenosine, and anti-inflammatory cytokines (e.g., IL-4, IL-10
and TGF-b) would induce AMPK activation in TAMs, TADCs,
and infiltrating T cells (Figure 2). This in turn, would lead to a
metabolic skewing of these cells toward oxidative phosphoryla-
tion, which supports their immunosuppressive phenotype, facil-
itating tumor growth. However, the role of AMPK might be more
complex due to its involvement in Th1 and Th17 development
and primary T cell responses to viral and bacterial infections
in vivo, reported recently (Blagih et al., 2015). Whether these
observations also hold true in cancer settings is still to be
ascertained.
HIF1a
HIF1a is an important transcription factor that orchestrates
response of mammalian cells to hypoxia (or low oxygen concen-
tration). Other stimuli such as LPS, bacteria, and fungi also acti-
vate HIF1a in monocytes, macrophages, and DCs (Cheng et al.,
2014; Rius et al., 2008; Shalova et al., 2015; Tannahill et al.,
2013). Hypoxia is a well-known tumor microenvironmental con-
dition and tumor-infiltrating myeloid cells like TAMs and MDSCs
demonstrate heightened expression of HIF1a expression (Mur-
doch et al., 2008). HIF1a is an important regulator of cellular
metabolism and function in these cells. Several glycolysis-444 Immunity 43, September 15, 2015 ª2015 Elsevier Inc.related genes like GLUT1, HK2, and PFKFB3 are direct target
genes of HIF1a (Semenza, 2003), Thus, HIF1a activation in im-
mune cells is closely linked to glycolysis (Figure 2). The role of
HIF1a in different immune cell types might vary. For example,
HIF1a induces inflammatory cytokines and ‘‘trained immunity’’
in LPS- and b-glucan-treated glycolytic macrophages, respec-
tively (Cheng et al., 2014; Tannahill et al., 2013). HIF1a also reg-
ulates angiogenic and tissue remodelingmolecules (e.g., VEGFA
andMMPs) and functions inmonocytes andmacrophages (Fang
et al., 2009; Shalova et al., 2015). Thus, HIF1a by driving inflam-
mation, angiogenesis, and tissue remodeling is well-suited to
orchestrate a tumor promoting phenotype in macrophages.
However, it is not clear whether HIF1a induces all these functions
via a metabolic reprogramming through glycolysis. Interestingly,
HIF1a can also contribute to immunosuppression through
tumor-derived lactic acid, induction of PD-L1 expression on
MDSCs, MDSC differentiation, and expansion of Treg cells
(Ben-Shoshan et al., 2008; Colegio et al., 2014; Corzo et al.,
2010; Noman et al., 2014). Collectively, these observations sug-
gest HIF1a to regulate the functional plasticity of immune res-
ponse during tumor progression. For example, during tumor
onset, HIF1a activation in TAMs might upregulate glycolytic
metabolism and support cancer-related inflammation (via IL-1b
production), whereas in established tumors, HIF1a expression
in TAMs, MDSCs, DCs, and Treg cells would collectively pro-
mote angiogenesis and immunosuppression (via lactic acid,
PD-L1 expression, adenosine-adenosine receptor interaction
on DCs, etc.) to sustain tumor growth (Figures 2A–2C). This is
in line with the recently described role of HIF1a in driving the
plasticity of human monocytes in sepsis (Shalova et al., 2015).
Further studies on the temporal regulation of HIF1a and meta-
bolismwill shed light on the link betweenmetabolic and immuno-
logical plasticity of tumor infiltrating immune cells.
c-Myc
The oncogenic transcription factor c-Myc has a regulatory effect
on multiple metabolic processes. For example, c-Myc in combi-
nation with HIF can induce the expression of glucose transporter
and enzymes like lactate dehydrogenase A (LDHA) and pyruvate
dehydrogenase kinase 1(PDK1) to enhance glycolysis. c-Myc
has a major contribution in glutamine metabolism in cancer
(and stromal) cells by inducing the expression of glutamine
transporters (e.g., SLC5A1) and glutaminase 1 (GLS1), the initial
enzyme of glutaminolysis (Gao et al., 2009; Wise et al., 2008). In
activated T cells, c-Myc controlled metabolic reprogramming by
regulating their metabolic transcriptome and thereby impacting
glycolysis, glutaminolysis, and polyamine synthesis (Wang
et al., 2011). Moreover, c-Myc controls the M2 polarization and
tumor-promoting function of TAMs by regulating pro-tumor fac-
tors like CCL18, TGF-b, VEGF, and MMP9 (Pello et al., 2012a;
Pello et al., 2012b) (Figure 2A, right panel). However, what are
themetabolic effects of c-Myc in TAMs andwhether thesemeta-
bolic events mediate the pro-tumor activity of these cells is not
yet known.
p53
The transcription factor and tumor suppressor p53 is a regulator
of metabolism. p53 regulates glucose metabolism in multiple
ways: it induces expression of the glycolysis enzyme HK2, it
suppresses glycolysis by upregulating molecules such as
TP53-induced glycolysis and apoptosis regulator (TIGAR) and
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oxidative phosphorylation (Cairns et al., 2011). Thus, in tumor
cells, p53 loss would force a glycolytic pathway (Figure 1, inset),
whereas in stromal cells like TAMs, where p53 is activated (Lowe
et al., 2014), it should block glycolysis and support oxidative
phosphorylation, although this is yet to be proven (Figure 2A,
right panel). In support, p53 was recently implicated in regulation
of M2 macrophage polarization (Li et al., 2015). It would be inter-
esting to see how p53 impacts the metabolic characteristics of
these polarized cells.
PPARs and LXRs
PPARs and LXRs are ‘‘lipid sensing’’ nuclear receptors that are
activated by free fatty acids, eicosanoids, prostaglandins, or
cholesterol metabolites. Upon activation, they bind to their target
gene promoter, inducing or repressing its expression. PPARg
was shown to regulate the alternative (or M2) activation of mac-
rophages and metabolic homeostasis (Liao et al., 2011; Ode-
gaard and Chawla, 2011). In a cancer setting, PPARg activation
had an anti-tumor effect on cancer cells, whereas its activation in
myeloid cells (e.g., macrophages) promoted lung tumor progres-
sion and metastasis (Li et al., 2011). PPARd has been implicated
in the clearance of apoptotic cells (Odegaard and Chawla, 2011).
This might be important in tumors, where dead cancer cells
are believed to polarize TAMs. In lung cancer, tumor cells
by inducing fatty-acid synthase and PPARb/d activation in
TAMspolarizes them into an IL-10 expressing, pro-tumor pheno-
type (Park et al., 2015). Similarly, phagocytosis of apoptotic
tumor cells (which contain oxysterols) would activate LXRs in
macrophages resulting in an immunosuppressive phenotype
(Traversari et al., 2014). In fact, LXR activation by tumor-derived
oxysterol also suppresses DC migration and neutrophil recruit-
ment into tumors, as well as interferes with tumor-infiltrating
antigen-specific T cells, which results in tolerance and immuno-
suppression (Traversari et al., 2014). Whether PPARs and LXRs
mediated these effects by modulating cell-intrinsic metabolism
remains to be characterized. This might be possible because
both these nuclear receptors regulate a number of glucose and
lipid metabolism genes.
Besides the molecules described above, recent studies have
revealed several other players. Compliments contribute to can-
cer-related inflammation by modulating tumor-infiltrating im-
mune cells (e.g., TAMs) (Bonavita et al., 2015). Recent evidence
implicates complements in regulating immune cell metabolism
and their effector functions (Kolev et al., 2015). Thus, in tumors
too, compliments might regulate the metabolism and function
of infiltrating immune cells. MicroRNAs can also serve as meta-
bolic regulators, since they are known to regulate energy meta-
bolism in cancer cells, immune cells, and CAFs (Ghesquiere
et al., 2014). Microbiota through the metabolism of bile acids,
hormones, alcohol, and its metabolites (e.g., deoxycholic acid)
can impact cancer progression (Schwabe and Jobin, 2013).
However, whether these microbial metabolites regulate cancer
promotion by polarizing the tumor-associated immune cells re-
mains to be investigated.
Concluding Remarks and Therapeutic Implications
Metabolic changes in immune cells regulate their phenotype and
function. This is also true for the tumor microenvironment. While
tumor cells opt for metabolic changes like glycolysis to supporttheir biosynthetic and energetic needs for rapid proliferation
and survival in hypoxic tumor microenvironments, evidence sug-
gests that the infiltrating immune cells (e.g., TAMs, TADCs,
MDSCs, T cells, neutrophils, B cells, and NK cells) also undergo
metabolic alterations that contribute to their pro- or anti-tumor
functions. These observations suggest (1) a metabolic dialog be-
tween tumor cells and these stromal immune cells and (2) a close
link betweenmetabolic reprogramming of immune cells and their
plasticity during tumor growth. For example, during the onset of
tumor, glycolytic metabolism in TAMs would induce inflamma-
tory cytokines, RNI, and ROS production, which support onco-
genic transformation and cancer-related inflammation. Later, in
established tumors, nutrient deprivation and accumulation of
metabolites like lactic acid and adenosine would induce oxida-
tive phosphorylation in TAMs and DCs to drive them to an immu-
nosuppressive phenotype. ARG1 and IDO activity in these cells
and MDSCs also induce amino acid deprivation in the tumor
microenvironment. Collectively, these events together with
metabolic changes in T cells would inhibit anti-tumor T effector
cell response, induce Treg cell response and mediate immuno-
suppression, thereby promoting tumor progression. A system-
atic profiling of tumor-associated immune subsets at a transcrip-
tional, metabolic, and function level would shed light on several
issues such as how metabolic changes regulate the transcrip-
tional and functional phenotype of these cells, what are the com-
mon and divergent metabolic characteristics between these
different immune cell types and tumor cells, and whether the
metabolic characteristics of these cells remain stable or change
in course of tumor progression, indicating a metabolic plasticity.
Mechanistically, various metabolites and metabolic regulators
such as lactic acid, HIF1, c-Myc, AMPK, and mTOR, which con-
trol metabolic reprogramming of immune cells and tumor cells,
are being tested for targeting. Drugs targeting lactate transporter
MCT1 andMCT2 (Doherty andCleveland, 2013) and AMPK (e.g.,
Metformin) are being evaluated for anti-tumor effects in preclin-
ical models and in clinical trials (Kim et al., 2014). Interestingly,
besides affecting tumor cells, Metformin has a direct effect on
infiltrating immune cells: increasing CD8+ T cell recruitment, pro-
tecting them from apoptosis and exhaustion, increasing CD8+
memory T cells, and providing a better response to anti-cancer
vaccines (Eikawa et al., 2015). The PD-1-PD-L1 pathway, a
prominent target in cancer immunotherapy, also induces meta-
bolic reprogramming of T cell metabolism (Patsoukis et al.,
2015). Thus, future studies identifying metabolic targets com-
mon to cancer cells and tumor promoting immune cells will not
only pave way for devising a two-pronged attack on cancer
and its stroma but also open new options for ‘‘re-purposing’’ ex-
isting metabolic drugs. Using such drugs in combination with
conventional chemotherapy is already being evaluated in pre-
clinical settings.
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